Objective. The purpose of this study was to compare cancer detection rates of sonographically suspicious lesion-directed biopsies and random biopsies through transverse examination of prostate halves in 518 patients over 5 years. Methods. From 1998 to 2002, 518 patients were referred for prostate biopsies because of either elevated prostate-specific antigen (PSA) levels or abnormal digital rectal examination findings. On the basis of transverse examination of prostate halves by transrectal ultrasound, we performed lesion-directed biopsy of 3 to 5 cores if morphologically suspicious lesions existed on sonography or random biopsy of 3 cores if no obvious suspicious lesions existed. Biopsy specimens were put into 2 labeled containers. Pathologic results were correlated with random and lesion-directed guided locations. Results. Nine-hundred fifty-nine results were obtained from 439 random and 520 lesion-directed biopsies in 518 patients. Cancer was detected in 207 patients (40.7%). Patients with cancer who had PSA levels of 10.0 ng/mL or greater had higher proportions of bilateral cancer lesions than those with PSA levels of less than 10 ng/mL (P = 0.03). One hundred ten (25.1%) of 439 normal-appearing halves taken by random biopsy were tumor-positive compared with 200 (38.5 %) of 520 biopsies from halves with sonographically suspicious lesions. Regardless of having random or lesion-directed biopsies, patients with PSA levels of 10 ng/mL or greater had higher positive malignancy rates than those with PSA levels of less than 10.0 ng/mL (P < .001). In about 40 patients, a diagnosis was made by random biopsy from halves that were morphologically normal on sonography, not by lesion-directed biopsy from tumor-suspicious contralateral halves. Conclusions. Cancer detection rates of lesion-directed biopsies are superior to those of random biopsies regardless of PSA level.
ince 2002, prostate cancer has been the sixth most common malignancy and seventh leading cause of cancer death in male patients in Taiwan. Annually, prostate cancer is diagnosed in more than 2000 men, of whom about 750 die. 1 As in other Asian countries, there has been an obvious increase in the annual detection rate since the late 1990s. 2, 3 The clinical application of prostate-specific antigen (PSA) assays partly contributes to such progression because an increasing number of prostate biopsies are triggered by results of PSA screening. 4 Despite the increase in detection rates, tumors have not been detected at an earlier stage. Biopsy strategy has played an important role in the detection of early prostate cancer, particularly with the guidance of transrectal ultrasound (TRUS).
Generally, TRUS has been the reference standard biopsy modality in the diagnosis of prostate cancer because of its anatomic accuracy. However, it remains equivocal in improving diagnostic accuracy. Indeed, prostate cancer can present with hyperechoic, hypoechoic, or isoechoic lesions on TRUS examination, even mixed echoic lesions, which are always indistinguishable from benign prostate tissue. 5 Therefore, the biopsy protocol varies according to the operator's requirements. Most urologists have accepted that 6 random biopsy cores taken from 6 different topographic parts of the prostate provide a good probability of confirming the diagnosis of prostate cancer and estimating the local extent of the disease. 6 With suitable and sufficient local anesthesia for pain control, a greater number of biopsy cores seem to enhance detection rates. 7 Nevertheless, it remains unknown how many biopsies are required to detect prostate cancer with proper sensitivity and specificity or whether the required number of biopsy cores or biopsy strategy should change according to PSA levels, either to avoid unnecessary biopsy or to increase detection rates. One cause for this limitation is the lack of pathologic correlation with TRUS-imaged lesions, particularly according to PSA stratification. Some tumors may not evoke changes in echo texture because of small size; thus, a higher number of biopsy cores may be required from such patients. Moreover, it might not be difficult in advanced patients to reach sufficient diagnostic performance by using a standard sextant biopsy protocol without requiring a high number of biopsy cores.
Because our goal is to find early prostate cancer, it is also important in motivating urologists and patients to enhance biopsy detection rates by improving diagnostic accuracy, particularly in patients with PSA levels of less than 10 ng/mL. The efficacy of both lesion-directed and random biopsies is worth exploring. Consequently, we have described and compared cancer detection rates of sonographically suspicious lesion-directed biopsies and random biopsies based on examination of transverse halves in 518 consecutive patients over a 5-year period.
Materials and Methods
From 1998 to 2002, 518 consecutive patients were referred for prostate biopsies at National Cheng Kung University Hospital. Indications for prostate biopsy included elevated PSA levels (>4.0 ng/mL), abnormal digital rectal examination (DRE) findings, or incidental morphologically suspicious lesions on sonography. The ultrasound machine used for TRUS was a B-K Medical (Copenhagen, Denmark) model 1846. Patients were positioned in the right lateral position. Transrectal ultrasound examinations were always performed in a systematic fashion, beginning with the transverse examination from apex to base at both low and high magnification or in a reverse direction. Then the plane was switched from transverse to longitudinal, and the prostate was examined from mid to left lateral and from mid to right lateral in the sagittal plane.
The criteria for a morphologically cancer-suspicious lesion on sonography involved comparing the 2 transverse halves (Figure 1 ) of the prostate for asymmetry, hypoechoic areas, or heterogeneous echogenic areas and confirming these in the longitudinal plane, particularly when located within the peripheral zone of the gland. The lesions were documented and archived, as were the biopsy sites at the time of investigation.
Of the patients investigated, those who were found to have at least 1 tumor-suspicious lesion on sonography (n = 380) underwent lesiondirected biopsy at its transverse half. Each lesion-directed biopsy included 3 to 5 biopsy cores within or adjacent to the lesion, whereas 3 biopsy cores were randomly taken from the contralateral half of the prostate gland if TRUS showed a normal appearance. The remaining patients (n = 138), who had no sonographically cancer-suspicious lesions, underwent bilateral sextant random biopsy. All specimens were obtained with an automatic biopsy gun and an 18-gauge needle. Biopsy specimens were separately put into 2 labeled containers (either right or left half). They were fixed in formalin and evaluated by a pathologist using the Gleason grading system. Biopsy results were then correlated with random and lesion-directed locations. Results were significant at P < .05.
Results
A total of 959 biopsy results were obtained from 518 patients, including 439 random and 520 lesion-directed biopsies. The median patient age was 71 years (range, 43-90 years), and the median PSA value was 16.41 ng/mL (range, 0.9-39,362 ng/mL). Regardless of whether random or lesion-directed biopsies were performed, less than one sixth (25 [15.0%] of 167) of patients with PSA levels of less than 10.0 ng/mL had the diagnosis of prostate cancer; in contrast, that diagnosis was made in more than half (182 [51.9%] of 351) of patients with PSA levels of 10.0 ng/mL or greater. Among 217 patients with prostate cancer, the diagnosis was made during the study period in 5 patients who had at least 1 previous negative biopsy result. The patients with prostate cancer who had PSA levels of 10.0 ng/mL or greater were significantly older (median age, 73 years) than those in the other 2 groups (PSA 4-10 and ≤4.0 ng/mL: median ages, 67.5 and 68 years, respectively) (P = .03, 1-way ANOVA). Exclusive cancer lesions in the right and left halves were detected in 49 (23.7%) Lan et al Figure 1 . Morphologically cancer-suspicious lesions confirmed by histologic examination. A, A 60-year-old man had bilateral lesiondirected biopsies because of a high PSA level (89 ng/mL). Pathologic examination showed prostatic adenocarcinoma over bilateral halves. B, A 65-year-old man had lesion-directed prostate biopsy on one half and random biopsy on the other side because of a slightly elevated PSA level (4.6 ng/mL) and a hard nodule. Pathologic examination showed prostatic adenocarcinoma over bilateral halves. C, A 75-year-old man had lesion-directed prostate biopsy on one half and random biopsy on the right lateral aspect because of an elevated PSA level (10.2 ng/mL). Pathologic examination of the sonographically suspicious lesion showed prostatic adenocarcinoma, and the other showed no evidence of malignancy. D, A 72-year-old man had bilateral lesion-directed biopsies because of an elevated PSA level (43 ng/mL). Pathologic examination of both halves showed prostatic adenocarcinoma.
and 44 (21.3%) patients, respectively, and 109 (52.7%) had cancer lesions in both halves (5 patients unknown). Patients with cancer who had PSA levels of 10.0 ng/mL or greater had higher proportions of bilateral cancer lesions than those with PSA levels of less than 10 ng/mL (P = .03, χ 2 test). The median Gleason scores among these 3 groups were 6, 6, and 7, respectively. Among these groups, no significant differences in Gleason score (P = .38, 1-way ANOVA) were determined. A detailed description showing the basic characteristics of cancer according to serum PSA levels is provided in Table 1 .
Of the 518 patients investigated, 303 (58.5%) had abnormal DRE findings. Of those patients with abnormal DRE findings, 172 (56.8%) had a histologic diagnosis of prostate cancer. Patients with abnormal DRE findings had higher cancer detection rates than those with normal DRE findings (PSA <4.0 ng/mL, 7.14% versus 17.5%; PSA 4.0-10.0 ng/mL, 10.3% versus 20.0%; PSA >10.0 ng/mL, 19.6% versus 74.0%). Statistical significance was reached only in patients with PSA levels of 10.0 ng/mL or greater (P < .001, χ 2 test) ( Table 2) .
Three hundred eighty (73.4%) of the 518 patients investigated were found to have at least 1 tumor-suspicious lesion on sonography, and 140 (27.0 %) had bilateral morphologically suspicious lesions on sonography. Of those patients with suspicious lesions, 187 (49.2%) had a histologic diagnosis of prostate cancer; in contrast, among those patients without suspicious lesions (n = 128), only 20 (15.6%) had a diagnosis of prostate cancer. Of 439 normal-appearing halves taken by random biopsy, 110 (25.1%) were found to be tumor-positive, compared with 200 (38.5%) of 520 biopsies taken from halves with sonographically suspicious lesions. Regardless of whether random or lesion-directed biopsies were performed, patients with PSA levels of 10 ng/mL or greater had higher positive rates for malignancy than those with PSA levels of less than 10.0 ng/mL (P < .001, χ 2 test) ( Table 3 ). Conversely, among 207 patients with histologically diagnosed prostate cancer, 60 (27.6%) had the diagnosis by random biopsy taken from normal-appearing prostate halves, including 6 patients with PSA levels between 4 and 10 ng/mL and 54 patients with PSA levels of 10 ng/mL or greater. In all 8 patients with prostate cancer who had PSA levels of less than 4.0 ng/mL, the diagnosis was made by lesion-directed biopsy. Interestingly, in about 40 patients, prostate cancer was histologically diagnosed by random biopsy taken from morphologically normal halves on sonography rather than by lesion-directed biopsy taken from the contralateral halves with suspicious lesions.
During subsequent 3-year follow-up examinations, another 5 patients had prostate cancer diagnosed via transurethral resection of the prostate. Among these 5 patients, all had elevated prediagnostic PSA levels of greater than 4.0 ng/mL; 2 had abnormal DRE findings, and 2 had morphologically cancer-suspicious lesions on sonography.
Discussion
As in another study, 8 our results show that an elevated PSA level is significantly associated with a greater extent of prostate cancer at diagnosis, as well as the patient's age. Digital rectal examination can help spot prostate cancer; in this study, abnormal DRE findings were statistically significant in patients with PSA levels of 10.0 ng/mL or greater. Most importantly, regardless of the PSA level, lesion-directed biopsy is superior to random biopsy in the detection of prostate cancer based on transverse examination of lesion halves. Most patients with the diagnosis of prostate cancer had elevated PSA levels of 10.0 ng/mL or greater and most probably had an Author: Please verify 518 as changed from 508. Also, please verify and most probably had an advanced stage of the disease as changed from more probably being in advanced state.
advanced stage of disease. Therefore, these data also lead us to reconsider performing biopsies either at younger ages or when PSA levels are lower for detecting earlier-stage prostate cancer. Our study showed that almost half of patients with sonographically suspicious lesions had the diagnosis of prostate cancer; in contrast, only one sixth of patients with sonographically normal-appearing prostates had prostate cancer. According to ethical acceptability, early detection of cancer should be focused on individuals who are likely to have the particular disease in a preclinical, detectable, and curable form and who are at high risk of ultimately suffering or dying of this disease without diagnosis. 9 In addition, unnecessary biopsy should be avoided when possible. In general, 1 prostate cancer should be detected from every 4 or 5 biopsies on the basis of screening ethical standards and pragmatism. Because prostate biopsy directed only to the hypoechoic lesion or standard sextant biopsy (Hodge scheme) is considered obsolete, the optimal prostate biopsy scheme that includes more than 6 cores (preferably 10-12 cores) weighted more laterally and apically might be considered to apply to patients with PSA levels of less than 10.0 ng/mL rather than those with PSA levels of 10.0 ng/mL or greater and to sonographically normal-appearing transverse halves rather than sonographically suspicious lesions. Nevertheless, among patients with PSA levels of less than 10.0 ng/mL, lesion-directed biopsy is superior to random biopsy with respect relation to cancer detection rates. Therefore, for patients with PSA levels of less than 10 ng/mL, it is important to recognize morphologically cancer-suspicious lesions found by TRUS imaging and to consider increasing the number of biopsy cores for those patients who have normal-appearing transverse prostate halves. For patients with PSA levels of 10.0 ng/mL or greater, both random and lesion-directed biopsy can play pivotal roles in diagnosing prostate cancer. When the number of biopsy cores is increased, caution should be used to avoid unnecessary pain and complications. 10 Because the superiority of lesion-directed biopsy has been shown, it is important to improve knowledge of the morphologic characteristics of prostate cancer on sonography. For example, a higher prevalence of cancer was discovered in prostates with hypoechoic areas. Loch et al 11 advocated that not only hypoechoic lesions but also asymmetry of the peripheral zone or bulging of the contour should be viewed as criteria for a suspicious lesion. In contrast, in a large series of 31,296 cores from 3912 patients, Onur et al 5 showed that the hypoechoic lesion itself was not associated with an increased cancer prevalence, and the cancer detection rate was not different between biopsy cores from isoechoic areas and hypoechoic lesions. Heijmink et al 12 promoted the utility of performing color or contrast-enhanced Doppler biopsies or adding these techniques to systematic biopsies to enhance diagnostic performance, even using 3-dimensional anatomic visualization. 13 Once a cancer-suspicious lesion has been visualized, it remains a challenge how to target and guide the needle into the lesion accurately. This problem may be one of the reasons that repeated biopsy is able to spot some prostate cancer in patients who had initial histologically benign biopsy results. Therefore, it is important for a learning urologist to become familiar with the skills of lesion-guided biopsies. Some investigators have thought that brachytherapy or cryotherapy of localized prostate cancer might provide opportunities to become more familiar with such techniques. 11, 14 Nevertheless, in several patients, prostate cancer was diagnosed from the normal-appearing half rather than from the suspicious lesion in the histologically normal contralateral half.
Our data also showed that DRE offered greater benefits for patients with PSA levels of 10.0 ng/mL or greater in aiding cancer detection than it did for those with PSA levels of less than 10.0 ng/mL. In fact, most patients with prostate cancer cases who had abnormal DRE findings in this study had PSA levels of 10.0 ng/mL or greater. This implies that DRE might not be helpful in the detection of early-stage prostate cancer. This agrees with a previous study. 15 Harris et al reported that DRE is a significant barrier to participation in prostate cancer screening. Not only does DRE make patients uncomfortable and embarrassed, with low compliance for repeated visits, 16 but PSA-plus DRE-based programs also result in fewer cases of prostate cancer detected, with a significant increase in negative biopsy results. 17 Because no correlation was shown between DRE, biopsy findings, and pathologic staging in patients with PSA levels between 2.5 and 10.0 ng/mL, Philip et al 18 suggested that DRE may not be essential for such patients. Even so, some investigators thought that DRE was still required to avoid nondetection during prostate cancer screening. 19 In conclusion, our data show that the cancer detection rate of lesion-directed biopsy is superior to that of random biopsy, regardless of the PSA level, indicating the importance of developing skills for recognizing morphologically suspicious lesions on sonography. Moreover, in some patients, prostate cancer was diagnosed from a sonographically normal-appearing half, whereas contralateral cancer-suspicious lesions were histologically benign. Therefore, routine contralateral random biopsy is required for patients with unilateral suspicious lesions. To increase detection of prostate cancer, a higher number of biopsy cores may be required for patients with PSA levels of less than 10.0 ng/mL. Our results also show that DRE plays a limited role in the early detection of prostate cancer.
